A 32-year-old man from rural Maharashtra presents with jaundice, dark urine, and abdominal pain for 10 days. He reports consuming water from a hand pump 4 weeks ago. On examination: icterus present, liver edge palpable 2 cm below costal margin, tender. Spleen not enlarged. Laboratory findings: total bilirubin 8.2 mg/dL (direct 6.1 mg/dL), AST 1240 IU/L, ALT 1680 IU/L, ALP 320 IU/L, INR 1.1, albumin 3.8 g/dL. Serological tests: anti-HAV IgM positive, anti-HBc negative, anti-HCV negative. What is the most appropriate management at this stage?

Explanation

## Diagnosis and Clinical Context **Key Point:** This patient has acute hepatitis A (HAV) confirmed by anti-HAV IgM positivity, with a typical prodrome (contaminated water 4 weeks prior) and acute hepatitis biochemistry. ## Why Supportive Care Is the Standard Acute hepatitis A is a **self-limited viral infection** with no specific antiviral therapy proven to alter the course. Management is entirely supportive: 1. **Bed rest and nutritional support** — allow hepatic regeneration 2. **Monitor coagulation (INR), bilirubin, and mental status** — early warning signs of fulminant hepatic failure 3. **Avoid hepatotoxic drugs** (acetaminophen, NSAIDs, alcohol) 4. **Fluid and electrolyte balance** **Clinical Pearl:** The INR is currently normal (1.1) and albumin preserved (3.8 g/dL), indicating preserved synthetic function — this patient is in the acute phase but NOT yet in fulminant failure. Prognosis in acute HAV is excellent; >99% of immunocompetent adults recover completely within 3–6 months. ## Monitoring for Complications **High-Yield:** Fulminant hepatic failure (FHF) occurs in <1% of HAV cases but is a medical emergency. Red flags include: - INR >1.5 (not present here) - Encephalopathy - Hypoglycemia - Rapid rise in bilirubin with falling transaminases ("peak and fall" pattern) If FHF develops, then transplant evaluation becomes necessary — but this patient does not currently meet criteria. ## Why Other Options Are Wrong **Ribavirin + IFN-α:** No evidence for benefit in acute HAV; these are used for chronic HCV, not acute HAV. **Corticosteroids:** Not indicated in acute viral hepatitis and may worsen outcomes by impairing immune clearance of virus. **Liver transplant:** Reserved for fulminant hepatic failure with contraindications to recovery; this patient has preserved synthetic function and no encephalopathy.